10x Genomics, Inc. (TXG) Comparison with companies in other sectors?

10x Genomics, Inc. has a share price of 124.85M. You can analyze 10x Genomics, Inc. (TXG) competitors across different market sectors through stock heatmaps.

What are TXG's NET and operating margins?

10x Genomics, Inc. (TXG) operating margin is around -0.28, and net profit margin is approximately -0.25 as of the latest reports.

In what way does TXG's earnings per share (EPS) trend reflect its financial momentum?

10x Genomics, Inc. (TXG) EPS is -1.30 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for 10x Genomics, Inc. is -10.85, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for 10x Genomics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for 10x Genomics, Inc. like P/E which is -10.88, P/B which is 2.42, and PEG which is -0.76. Compare them with sector averages to evaluate if the stock is priced fairly.

10x Genomics, Inc.

TXG•NASDAQ

Healthcare

Medical - Healthcare Information Services

$14.11

$0.38(2.77%)

Fundamental Analysis of 10x Genomics, Inc. (TXG)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-1.30

P/E Ratio

-10.85

ROE

-0.22%

Net Margin

-0.25%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.76B

Shares OutstandingTotal number of shares issued

$124.85M

Book Value/ShareNet worth per share

$5.77

Revenue/ShareAnnual revenue per share

$5.09

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-1.3

Net MarginNet income as percentage of revenue

-25.14%

Operating MarginOperating income as percentage of revenue

-27.60%

ROEReturn on shareholders' equity

-21.93%

ROAReturn on total assets

-17.38%

ROCEReturn on capital employed

-21.67%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.36

Cash/ShareCash and equivalents per share

$3.48

FCF YieldFree cash flow as percentage of market cap

2.50%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for TXGFinancial Ratios Analysis details for TXG are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for TXGSector Benchmarking details for TXG are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for 10x Genomics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of 10x Genomics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account 10x Genomics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for 10x Genomics, Inc.

For 10x Genomics, Inc., essential financial indicators include EPS -1.30, PE -10.85, and ROE -0.22. These key ratios reveal insights into 10x Genomics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare 10x Genomics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of 10x Genomics, Inc.

Metrics like Net Margin -25.14% and ROA -17.38% shed light on how well 10x Genomics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether 10x Genomics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of 10x Genomics, Inc.

Using ratios such as P/B Ratio 2.42 and PEG Ratio -0.76, investors can assess whether 10x Genomics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with 10x Genomics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for 10x Genomics, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.11 and Cash Flow $0.36, provide a snapshot of 10x Genomics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like 10x Genomics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for 10x Genomics, Inc.

Investing in 10x Genomics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at 10x Genomics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;